RxDoctor Payments Data

Christine Tremblay, DO

Family Medicine · Wells, MENPI 1457434573

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 49.2% of the total.

$768in general payments, 2019–2025

Across 30 payments — averaging $25.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$378
  • AstraZeneca$125
  • GSK$125
  • Novartis$46
  • Exact Sciences$34
  • Alkermes, Inc.$29
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$768100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie21$378
AstraZeneca1$125
GSK1$125
Novartis3$46
Exact Sciences1$34
Alkermes, Inc.1$29
Abbott1$15
Pfizer1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$768 in reported general payments places this provider in the 85th percentile of 466 family medicine providers in Maine.

See all family medicine providers in Maine

Medicare billing

Part B allowed, 2024
$63,072
Medicare patients
226
Services billed
659

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide63$69,320
EliquisApixaban47$65,403
JardianceEmpagliflozin12$18,187
MounjaroTirzepatide13$13,186
SynthroidLevothyroxine Sodium62$4,381
Atorvastatin Calcium295$3,220
Lantus SolostarInsulin Glargine,hum.Rec.Anlog25$3,068
Arnuity ElliptaFluticasone Furoate12$2,377
Levothyroxine Sodium210$2,294
Duloxetine Hcl34$2,214
Advair DiskusFluticasone Propion/Salmeterol11$2,037
Omeprazole124$2,034
Rosuvastatin Calcium120$1,657
Gabapentin86$1,637
Escitalopram Oxalate91$1,572

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$65,40347 claims
AbbVieSynthroid$378$4,38162 claims
GSKArnuity Ellipta$125$2,37712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 466 family medicine providers in Maine.

Other family medicine in Wells

See the full list for Maine

Where these figures come from

Is this you, or does something look wrong? →